Premium
CalciMedica Inc (CALC)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune... CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. Show more
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference PR Newswire LA JOLLA, Calif., Nov. 21, 2024 LA JOLLA, Calif., Nov. 21, 2024 /PRNewswire/ -- CalciMedica Inc...
CalciMedica Announces Presentations at Upcoming Medical Meetings PR Newswire LA JOLLA, Calif., Nov. 20, 2024 Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™...
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates PR Newswire LA JOLLA, Calif., Nov. 13, 2024 Additional positive data, including a win ratio...
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer PR Newswire LA JOLLA, Calif., Nov. 7, 2024 LA JOLLA, Calif., Nov. 7, 2024 /PRNewswire/...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.34 | -10.0294985251 | 3.39 | 3.5 | 3.02 | 32684 | 3.2186601 | CS |
| 4 | -0.52 | -14.5658263305 | 3.57 | 3.6 | 3.02 | 51048 | 3.41746796 | CS |
| 12 | -1.81 | -37.2427983539 | 4.86 | 5.65 | 2.91 | 51462 | 3.88340681 | CS |
| 26 | -2.44 | -44.4444444444 | 5.49 | 5.97 | 2.91 | 48511 | 4.04767341 | CS |
| 52 | -0.98 | -24.317617866 | 4.03 | 8.38 | 2.68 | 33843 | 4.27104515 | CS |
| 156 | -13.33 | -81.3797313797 | 16.38 | 16.38 | 1.17 | 14704 | 4.12257497 | CS |
| 260 | -13.33 | -81.3797313797 | 16.38 | 16.38 | 1.17 | 10555 | 4.12257497 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
